Modelled DT Structure
Method: multi-sequence alignment based machine learning
Detail: Structure Info
General Information of DT | |||||
---|---|---|---|---|---|
DT ID | DTD0393 | ||||
Gene Name | SLC52A1 | ||||
Protein Name | Riboflavin transporter 1 | ||||
Gene ID | |||||
UniProt ID | |||||
TCDB ID | |||||
3D Structure |
Modelled DT Structure Method: multi-sequence alignment based machine learning Detail: Structure Info |
||||
Synonyms | GPCR42; GPR172B; PAR2; PERV-A receptor 2; Porcine endogenous retrovirus A receptor 2; Protein GPR172B; RBFVD; RFT1; RFVT1; SLC52A1; Solute carrier family 52, riboflavin transporter, member 1; hRFT1 | ||||
DT Family | Eukaryotic Riboflavin Transporter (E-RFT) Family ; | ||||
Tissue Specificity | Widely expressed. Highly expressed in thetestis, placenta and small intestine. Expressed at lower level inother tissues. | ||||
Function | This Na(+)-independent transporter mediates the transport of riboflavin. Activity is strongly inhibited by riboflavin analogs, such as lumiflavin. Weakly inhibited by flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN). | ||||
Variability Data of This Drug Transporter (DT) | |||||
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
(β) Post-translational Modification of This DT |
|||||
(γ) Transcriptional Regulation of This DT |
|||||
(δ) Epigenetic Regulation of This DT |
|||||
General Variability Data of This DT (VARIDT 1.0) |
|||||
(β) Disease-specific Protein Abundances of This DT |
|||||
(γ) Species- and Tissue-specific DT Abundances |
|||||
Molecular Transporting Profile of This DT | |||||
Full List of Drug(s) Transported by This DT |
|||||
Approved Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
Riboflavin
|
Approved | Drug Info | Acne vulgaris | ED80 | [1] |
References | |||||
1 | An intronic variation in SLC52A1 causes exon skipping and transient riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Mol Genet Metab. 2017 Dec;122(4):182-188. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.